You were told fibromyalgia. Could it still be the benzodiazepine?
It could, and in a patient with your history it often is, at least in part. Fibromyalgia describes widespread pain, exhaustion that sleep does not touch, and a fog that swallows words, and the diagnosis may be accurate as far as it goes. What the chart may not record is a decade on a benzodiazepine, or that the pain arrived during the taper.
Benzodiazepine-induced neurological dysfunction, or BIND, is the name for the pain, sensory, cognitive, and autonomic symptoms that can follow long-term benzodiazepine use, during a taper and long after it. Put that list beside the fibromyalgia list and the overlap is nearly complete.
So, which one do you have? For many patients the label depended on which door they walked through, and the rheumatology door had no reason to ask about a sleeping pill. How do you tell the two apart, and why does it matter which name goes first?
Why do the two pictures look so alike?
Both fibromyalgia and BIND are understood as a nervous system that has turned up its own volume, so that ordinary signals from muscles and joints are felt as pain. That is as far as the mechanism needs to go. What separates the two is what turned the volume up.
The Ashton Manual, in Chapter 3, lists pain and stiffness in the limbs, back and neck in its Table 1 of withdrawal symptoms, with fatigue and influenza-like symptoms beside them, which reads like a fibromyalgia note. In BIND, though, the cause has a name and a date on a pharmacy label.
A homely picture may help, with limits. Two different leaks can leave the same stain on a ceiling, and staring at the stain will not tell you which pipe. While this is not a perfect analogy, since a nervous system can spring two leaks at once, the instruction holds: before anyone treats the stain, ask what changed upstairs, and when.
The timeline is the first thing that tells them apart.
Pain and fatigue that began during a taper, or after years of stable dosing once the drug had stopped working, point toward BIND. Pain that predates the first prescription by years points toward fibromyalgia of its own. The question is rarely asked, because the benzodiazepine seldom makes the list of suspects. It is usually filed under treatments.
A common pattern is a woman in her fifties who took a benzodiazepine for sleep for fifteen years, was taken off it over a few weeks, and six months later carries a fibromyalgia diagnosis and a prescription for pregabalin. The taper is nowhere in the rheumatology note. Nobody lied, and nobody connected the dates.
Raising the history yourself can feel like confessing to something. Physical dependence is not addiction. It is the nervous system’s adaptation to a medication taken as prescribed, and what follows a dose reduction is that adaptation unwinding, with no verdict on your character attached.
The autonomic and sensory picture is the second.
BIND tends to bring a louder autonomic picture: temperature swings, a pounding heart on standing, blood pressure that lurches, sweating with no exertion, and gut symptoms that track dose changes. Fibromyalgia can include some of this, but it is seldom the loudest part.
Sensory hypersensitivity is the other tell. The Ashton Manual calls a heightened sensitivity to hearing, sight, touch, taste and smell a characteristic feature of withdrawal, with clocks unbearably loud and ordinary light dazzling. Patients with BIND also describe new reactions to medications and foods they once tolerated, which is far less usual in a fibromyalgia history.
The same collision has sent patients with BIND through a multiple sclerosis workup and into allergy testing. Each time a real symptom pointed at the wrong diagnosis.
Windows and waves are the third.
Fibromyalgia fluctuates, but its swings do not usually follow a calendar you can read. BIND does. The Ashton Manual describes symptoms that wax and wane from day to day and week to week, with windows of normality, hours or days of feeling positively well, appearing after some weeks. Patients call the bad stretches waves.
The difference is time-locking. Waves in BIND tend to follow a dose reduction by a few days, or a new medication, an infection, or a hard week, and the window afterward is often unmistakable. So, keep a calendar with the reductions on one side and the worst days on the other, and see whether they keep landing in the week or two after each cut.
Can you have both?
Yes, and many patients do. Fibromyalgia that predates the benzodiazepine by years is real, and a taper can make it far worse for a time, since one sensitized nervous system is being pushed from two directions. The honest chart entry is then fibromyalgia with a BIND contribution, or, often, BIND that happens to meet fibromyalgia criteria.
Dr. Leeds’ view is that the earlier label need not be erased. Both can stand, each explaining part of the picture, and while the taper is under way or recently finished, the BIND piece leads.
The standard fibromyalgia drugs each carry a second taper inside them.
The medicines most often prescribed for fibromyalgia are duloxetine and milnacipran, which are serotonin and norepinephrine reuptake inhibitors, or SNRIs, the gabapentinoids pregabalin and gabapentin, and amitriptyline, a tricyclic antidepressant. Whether one helps you is between you and your doctor. What is not in question is that each brings its own dependence or discontinuation problem into a nervous system that already has one.
Gabapentin and pregabalin produce physical dependence of their own, with a withdrawal syndrome that looks, in many respects, like the one you are already in. Taken alongside a benzodiazepine they also add to its sedation and can slow breathing, so every prescriber on your list needs to know about the benzodiazepine.
The SNRIs are a different class, but their discontinuation symptoms are real and can be slow to taper, which is why the Maudsley Deprescribing Guidelines give antidepressants and gabapentinoids their own sections beside the ones for benzodiazepines. Amitriptyline has a discontinuation syndrome of its own, and at the low doses used for pain it is often as much a tolerance problem as a taper problem, since its anticholinergic effects land hard on a nervous system already reacting to everything.
So, the price of short-term relief is often a second taper later, and for a patient still on the benzodiazepine, one more drug in the deprescribing plan. That is not a rule against them, and some patients, with their doctor, decide that relief now is worth it, so long as the price is written down before the first dose rather than discovered after the last.
What about exercise and therapy?
Graded exercise, where the amount goes up on a schedule regardless of how you feel, is standard fibromyalgia advice. Patients with BIND often describe a crash a day or two after exertion, and a schedule that ignores the crash produces more of them. The Ashton Manual recommends regular moderate exercise during withdrawal, and moderate is the word to hold onto.
Pacing means doing what today allows, stopping before the crash, and adding a little as the windows lengthen. It is slower than a graded program, and it is the approach that tends to hold up in BIND, because it is the one patients keep up.
Cognitive behavioral therapy, or CBT, can help when it is offered as tools for living with a neurological syndrome, and lands as one more dismissal when it is offered as treatment for a psychological condition. Most patients with BIND have collected several already.
Sometimes the pain is neither, and it needs to be checked.
Both labels come after other things have been looked at. Widespread pain with a fever, unexplained weight loss, night sweats, hot or swollen joints, a new rash, weakness or numbness on one side, or pain with no relationship to your dose changes should be examined rather than filed under either name.
Chest pain, a seizure, a sudden loss of vision or hearing, or thoughts of harming yourself are reasons for emergency care that day, and in the United States a call or text to 988 reaches the Suicide and Crisis Lifeline. A taper never makes any of those safe to wait on.
Neither does it make stopping safe. The 2020 United States Food and Drug Administration (FDA) benzodiazepine label update warns that abrupt discontinuation or rapid dose reduction can bring on acute withdrawal reactions, including seizures, and describes a protracted withdrawal syndrome lasting weeks to more than a year. If the pain is the taper, the answer is a slower taper, decided with your doctor, never a faster one.
The diagnosis is worth revisiting over time.
Fortunately, BIND has a direction. The Ashton Manual says a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time, and BIND-dominant pictures tend to keep improving for months, sometimes years, after the taper is complete. No one can give you the date, and an honest doctor will say so.
That direction is also a diagnostic test. Whatever pain and fatigue remain after the BIND curve has run its course are better evidence for fibromyalgia of its own, and can be treated as such once the nervous system is better able to tolerate treatment.
So, treat the line on your chart as a working hypothesis rather than a verdict. Bring the calendar and the dates, and ask your doctor which name should lead for now. As the waves thin out, the two of you can look again, and the answer may be smaller than it is today.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.